John M Canio, MD
Internal Medicine · Roseville
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 5
- Since medical school
- 32 years
- Howard University College of Medicine, 1994
Offices
5 locations · Capitol Gastroenterology Consultants Medical Group Inc · Benefis Hospitals Inc
Hospitals listed: Benefis Hospitals Inc · Mercy San Juan Medical Center · Sutter Roseville Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Canio’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A54545 · Current
Licensed to practise in California · since 1995 · expires 2027-03-31 · Howard University College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Surgery centers they own
- Folsom Endoscopy Center LLC dba Folsom Sierra Endoscopy CenterAmbulatory Surgery Center · Folsom, CA2% owner since 2020 · accredited by AAAHCAccreditation Renewed2 inspections, 1 with deficiencies · last 2024-03-14: Requirements Met
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Gastroenterology
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 80.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Benefis Hospitals IncGreat Falls, MTAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Benefis Health System, which runs 3 hospitalsPatients rate it 3 of 5 · 62% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.603, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.301, Oct 2024 – Sep 2025
- Mercy San Juan Medical CenterCarmichael, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 3 of 5 · 69% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.108, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.144, Oct 2024 – Sep 2025
- Sutter Roseville Medical CenterRoseville, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 79% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Pressure ulcer rate: 0.08 (0 to 0.56) · 12,400 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.069, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.262, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.128, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.357, Oct 2024 – Sep 2025
See every measure and the patient survey for Benefis Hospitals Inc
Behind the star rating — Deaths: 0 better, 4 the same, 4 worse of 8 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 2 better, 9 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.603 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.301 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.78 (0 to 1.73) · 1,156 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.92 (0.58 to 1.25) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 202.45 (152.17 to 252.73) · 68 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 4.7 · 44 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 11.7 · 109 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.1 · 162 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 15 · 250 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 24.6 · 340 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 13.2 · 197 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.5 · 2,073 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.32 (0.11 to 0.53) · 5,248 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.33 (0.13 to 0.53) · 5,263 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.96 (0.94 to 4.99) · 1,458 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.88 (0.26 to 3.5) · 586 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.91 (0.44 to 3.38) · 1,414 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.47 (0.34 to 14.6) · 596 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.63 (0.87 to 8.39) · 544 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.55 (0.11 to 2.98) · 366 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.61 (0 to 1.33) · 4,353 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.4 · 37 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.961 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.994 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.6 · 134 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.9 · 291 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 9.7 · 166 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 1.6 · 263 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -16 · 325 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.6 · 363 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.1 (3.6 to 7.3) · 264 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.7 (7.3 to 12.7) · 264 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 28 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.4 · 33 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.9 · 153 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.3 (9.5 to 15.9) · 1,335 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.3) · 696 cases | No different | Jan 2024 – Dec 2024 |
What patients said (395 patients answered, 23% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 3 |
| Recommend hospital | 3 |
| Room was "always" clean | 64% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 79% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 62% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 62% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Mercy San Juan Medical Center
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 1 better, 8 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.108 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.144 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.78 (0 to 1.72) · 1,413 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.77 (0.47 to 1.07) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 195.56 (150.94 to 240.19) · 122 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 9.6 · 193 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 14.6 · 190 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12.9 · 445 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.7 · 444 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.2 · 518 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 3,727 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.39) · 8,263 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.05 to 0.42) · 8,488 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.3 (0.42 to 4.18) · 1,992 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.38 (0 to 2.95) · 566 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.08 (0.71 to 3.44) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.41 (0 to 13) · 533 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.3 (0.68 to 7.92) · 557 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.6 (0.14 to 3.06) · 338 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.53 (0 to 1.11) · 7,155 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.3 · 48 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.567 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.1 · 283 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.2 · 852 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.4 · 183 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -14.6 · 522 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -12.4 · 458 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.9 · 708 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.9 (3.1 to 7.5) · 102 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10 (7 to 14) · 102 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 57 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.3 · 51 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 379 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (9.5 to 17.2) · 384 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.4) · 291 cases | No different | Jan 2024 – Dec 2024 |
What patients said (611 patients answered, 17% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 64% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 68% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 41% |
| "YES", patients would definitely recommend the hospital | 69% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Sutter Roseville Medical Center
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 5 better, 1 the same, 1 worse of 7 measures. Readmissions: 2 better, 7 the same, 1 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Pressure ulcer rateComplications and deaths | 0.08 (0 to 0.56) · 12,400 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.069 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.262 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.128 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.357 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.33 (0.49 to 2.17) · 2,916 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.9 (0.63 to 1.17) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 147.2 (107.33 to 187.07) · 191 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.9 · 250 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.7 · 484 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 839 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.3 · 1,027 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10 · 656 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.8 · 6,822 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.25 (0.08 to 0.42) · 14,300 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.06 to 0.41) · 14,490 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.43 (2.77 to 6.08) · 3,117 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.38 (0 to 2.95) · 938 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.06 (0.76 to 3.36) · 2,944 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.03 (2.8 to 15.25) · 840 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.43 (3.11 to 9.75) · 899 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.73 (0.34 to 3.11) · 819 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.4 · 35 cases | None | Apr 2023 – Mar 2025 |
| SSI - Colon SurgeryInfections | 0.41 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.9 · 527 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.6 · 1,094 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -16.6 · 443 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -11 · 961 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -8 · 1,064 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.1 · 1,293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (3.5 to 8.7) · 35 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (6.9 to 14.9) · 35 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 36 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.5 · 310 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.8 to 17.9) · 116 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 1,600 cases | No different | Jan 2024 – Dec 2024 |
What patients said (537 patients answered, 24% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 77% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 78% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$87,758
Medicare paid this office $87,758 for 371 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 121 | $15,468 | $103 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 79 | $15,332 | $192 |
| Short return visit (20+ min) | 125 | $10,776 | $70 |
| Biopsy of large bowel using a flexible endoscope | 114 | $9,936 | $86 |
| New patient visit (30+ min) | 93 | $7,677 | $83 |
See all 12 services
| Return visit (30+ min) | 121 | $15,468 | $103 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 79 | $15,332 | $192 |
| Short return visit (20+ min) | 125 | $10,776 | $70 |
| Biopsy of large bowel using a flexible endoscope | 114 | $9,936 | $86 |
| New patient visit (30+ min) | 93 | $7,677 | $83 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 88 | $5,732 | $62 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 21 | $3,856 | $184 |
| Insertion of guide wire with dilation of esophagus using a flexible endoscope | 19 | $2,190 | $110 |
| Diagnostic exam of large bowel using a flexible endoscope | 15 | $2,055 | $137 |
| Long return visit (40+ min) | 12 | $1,743 | $134 |
| New patient visit (45+ min) | 14 | $1,671 | $119 |
| New patient visit (15+ min) | 25 | $1,347 | $54 |
Procedures Medicare counted
| Colonoscopy | 282 | More than 97% of doctors who do this |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 194 | More than 90% of doctors who do this |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Biopsy of large bowel using a flexible endoscope | 121 | 97 | 138 | 131 | 121 | 115 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 105 | 84 | 112 | 109 | 104 | 92 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 64 | 49 | 86 | 106 | 109 | 80 |
| Diagnostic exam of large bowel using a flexible endoscope | 42 | 29 | 28 | 16 | 21 | 15 |
| Insertion of guide wire with dilation of esophagus using a flexible endoscope | 12 | 14 | 17 | 19 | 20 | 20 |
| Injection beneath lining of large bowel using a flexible endoscope | 11 | – | – | – | – | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
371 Original Medicare patients in 2024. Average age 74 · Under 65 5% · 85 and older 8% · Women 60% · Also on Medicaid 8% · Health risk score 0.96. At or below the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 69% · Diabetes 24% · Chronic kidney disease 22% · Coronary heart disease 20% · Cancer 18% · Depression 17% · Atrial fibrillation 14% · COPD 12% · Heart failure 10% · Stroke 4%.
The office billed $266,614, Medicare allowed $116,139 and paid $87,758; for 861 services of 33 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 371 | 861 | 74 | 0.96 | $266,614 | $87,758 |
| 2023 | 459 | 1,062 | 73 | 1.15 | $328,025 | $105,342 |
| 2022 | 518 | 1,108 | 73 | 1.00 | $319,576 | $107,810 |
| 2021 | 462 | 1,052 | 73 | 1.00 | $313,247 | $104,970 |
| 2020 | 432 | 947 | 73 | 1.20 | $278,132 | $91,501 |
| 2019 | 434 | 1,087 | 72 | 1.22 | $324,286 | $100,847 |
| 2018 | 592 | 1,631 | 72 | 1.44 | $448,289 | $144,376 |
| 2017 | 508 | 1,390 | 71 | 1.58 | $376,685 | $117,506 |
| 2016 | 565 | 1,437 | 71 | 1.40 | $369,193 | $117,424 |
| 2015 | 493 | 1,374 | 72 | 1.52 | $410,102 | $135,800 |
| 2014 | 408 | 1,212 | 71 | 1.48 | $417,454 | $113,553 |
| 2013 | 393 | 1,134 | 71 | 1.54 | $446,817 | $115,894 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 12 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 108 | $20,330 | $187 |
| Return visit (30+ min) | 135 | $16,977 | $94 |
| Short return visit (20+ min) | 152 | $12,294 | $68 |
| Biopsy of large bowel using a flexible endoscope | 120 | $9,048 | $75 |
| New patient visit (30+ min) | 108 | $8,294 | $77 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 100 | $6,267 | $60 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 22 | $3,975 | $181 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $3,841 | $137 |
| Diagnostic exam of large bowel using a flexible endoscope | 20 | $2,579 | $123 |
| Insertion of guide wire with dilation of esophagus using a flexible endoscope | 20 | $2,368 | $118 |
| New patient visit (15+ min) | 23 | $1,294 | $56 |
| Short return visit | 13 | $570 | $44 |
2022: 12 services
| Return visit (30+ min) | 187 | $26,118 | $100 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 105 | $20,640 | $195 |
| Biopsy of large bowel using a flexible endoscope | 131 | $10,896 | $83 |
| New patient visit (30+ min) | 112 | $9,590 | $86 |
| New patient visit (45+ min) | 63 | $8,172 | $130 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 105 | $7,417 | $68 |
| Short return visit (20+ min) | 99 | $6,598 | $60 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 19 | $3,640 | $192 |
| Diagnostic exam of large bowel using a flexible endoscope | 16 | $2,335 | $146 |
| New patient visit (15+ min) | 50 | $2,106 | $42 |
| Insertion of guide wire with dilation of esophagus using a flexible endoscope | 19 | $1,944 | $102 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 43 | $907 | $19 |
2021: 11 services
| Return visit (30+ min) | 199 | $29,488 | $101 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 85 | $17,107 | $199 |
| Biopsy of large bowel using a flexible endoscope | 135 | $13,093 | $95 |
| New patient visit (45+ min) | 78 | $8,870 | $114 |
| New patient visit (30+ min) | 109 | $8,551 | $78 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 110 | $7,200 | $64 |
| Long return visit (40+ min) | 26 | $4,117 | $147 |
| Diagnostic exam of large bowel using a flexible endoscope | 28 | $3,698 | $132 |
| Short return visit (20+ min) | 44 | $3,150 | $67 |
| Insertion of guide wire with dilation of esophagus using a flexible endoscope | 17 | $1,737 | $102 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 44 | $879 | $20 |
2020: 13 services
| Return visit (30+ min) | 206 | $24,787 | $81 |
| New patient visit (45+ min) | 106 | $12,958 | $122 |
| Biopsy of large bowel using a flexible endoscope | 97 | $11,071 | $114 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 49 | $9,299 | $190 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 83 | $5,437 | $65 |
| New patient visit (60+ min) | 27 | $4,485 | $166 |
| Diagnostic exam of large bowel using a flexible endoscope | 29 | $4,218 | $145 |
| Short return visit (20+ min) | 65 | $4,177 | $56 |
| New patient visit (30+ min) | 50 | $3,645 | $73 |
| Long return visit (40+ min) | 28 | $3,502 | $117 |
| Insertion of guide wire with dilation of esophagus using a flexible endoscope | 14 | $1,620 | $116 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 14 | $261 | $19 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 12 | $50 | $4 |
2019: 15 services
| Return visit (30+ min) | 163 | $21,007 | $86 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 64 | $12,741 | $199 |
| Biopsy of large bowel using a flexible endoscope | 120 | $12,375 | $102 |
| New patient visit (45+ min) | 64 | $8,372 | $131 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 105 | $7,079 | $67 |
| Short return visit (20+ min) | 91 | $6,546 | $60 |
| Diagnostic exam of large bowel using a flexible endoscope | 42 | $5,683 | $135 |
| New patient visit (30+ min) | 49 | $3,732 | $76 |
| Long return visit (40+ min) | 31 | $3,454 | $111 |
| New patient visit (60+ min) | 12 | $2,047 | $171 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,820 | $165 |
| Insertion of guide wire with dilation of esophagus using a flexible endoscope | 12 | $1,433 | $119 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 83 | $372 | $4 |
| Injection beneath lining of large bowel using a flexible endoscope | 11 | $304 | $28 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 14 | $141 | $10 |
2018: 21 services
| Return visit (30+ min) | 199 | $23,881 | $80 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 104 | $17,325 | $165 |
| Biopsy of large bowel using a flexible endoscope | 145 | $16,344 | $113 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 60 | $11,810 | $197 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 69 | $10,529 | $85 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 125 | $9,140 | $73 |
| Pathology examination of tissue using a microscope, intermediate complexity | 104 | $6,553 | $25 |
| Diagnostic exam of large bowel using a flexible endoscope | 42 | $5,672 | $135 |
| New patient visit (30+ min) | 78 | $4,842 | $62 |
| Short return visit (20+ min) | 65 | $3,425 | $50 |
| Long return visit (40+ min) | 29 | $2,881 | $96 |
| New patient visit (45+ min) | 28 | $2,854 | $102 |
| Breath test analysis for helicobacter pylori | 24 | $2,201 | $82 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 22 | $1,901 | $86 |
| Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 11 | $1,851 | $154 |
| Insertion of guide wire with dilation of esophagus using a flexible endoscope | 12 | $1,522 | $127 |
| Study of esophagus to assess movement | 15 | $827 | $55 |
| New patient visit (15+ min) | 14 | $746 | $53 |
| Injection beneath lining of large bowel using a flexible endoscope | 24 | $400 | $17 |
| Incision of pancreatic outlet using a flexible endoscope | 11 | $317 | $29 |
| Administration of drug for helicobacter pylori | 23 | $247 | $10 |
2017: 22 services
| Return visit (30+ min) | 167 | $15,320 | $74 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 81 | $13,285 | $154 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 128 | $8,883 | $67 |
| Biopsy of large bowel using a flexible endoscope | 97 | $8,597 | $87 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 41 | $8,317 | $189 |
| Diagnostic exam of large bowel using a flexible endoscope | 45 | $6,210 | $135 |
| Pathology examination of tissue using a microscope, intermediate complexity | 99 | $5,455 | $23 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 35 | $5,016 | $80 |
| Short return visit (20+ min) | 76 | $4,470 | $50 |
| New patient visit (30+ min) | 60 | $4,279 | $71 |
| Critical care, first 30-74 minutes | 13 | $3,045 | $169 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 35 | $2,757 | $55 |
| New patient visit (45+ min) | 22 | $2,459 | $112 |
| Insertion of stomach tube using a flexible endoscope | 11 | $2,028 | $156 |
| Long return visit (40+ min) | 18 | $2,010 | $112 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 11 | $1,992 | $181 |
| New patient visit (60+ min) | 11 | $1,715 | $156 |
| Insertion of guide wire with dilation of esophagus using a flexible endoscope | 12 | $1,631 | $125 |
| Breath test analysis for helicobacter pylori | 16 | $1,449 | $91 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 12 | $965 | $80 |
| Injection beneath lining of large bowel using a flexible endoscope | 14 | $480 | $32 |
| Administration of drug for helicobacter pylori | 16 | $169 | $11 |
2016: 17 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 89 | $14,180 | $158 |
| Biopsy of large bowel using a flexible endoscope | 108 | $12,292 | $113 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 48 | $9,661 | $197 |
| Pathology examination of tissue using a microscope, intermediate complexity | 123 | $8,039 | $28 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 107 | $7,998 | $74 |
| Return visit (30+ min) | 85 | $7,960 | $76 |
| Short return visit (20+ min) | 131 | $7,858 | $51 |
| Diagnostic exam of large bowel using a flexible endoscope | 50 | $7,112 | $142 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 65 | $6,007 | $56 |
| New patient visit (15+ min) | 75 | $3,634 | $48 |
| New patient visit (45+ min) | 26 | $3,048 | $117 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 24 | $2,553 | $106 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 13 | $2,475 | $190 |
| New patient visit (30+ min) | 43 | $2,305 | $54 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $1,133 | $81 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 11 | $1,027 | $93 |
| Short return visit | 23 | $668 | $28 |
2015: 21 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 105 | $17,623 | $165 |
| Biopsy of large bowel using a flexible endoscope | 96 | $13,657 | $139 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 47 | $11,110 | $236 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 106 | $10,057 | $59 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 110 | $9,219 | $82 |
| Return visit (30+ min) | 79 | $7,351 | $82 |
| Short return visit (20+ min) | 91 | $6,289 | $55 |
| New patient visit (30+ min) | 81 | $6,048 | $75 |
| Diagnostic exam of large bowel using a flexible endoscope | 32 | $5,631 | $176 |
| New patient visit (45+ min) | 42 | $4,946 | $118 |
| Pathology examination of tissue using a microscope, intermediate complexity | 75 | $4,894 | $29 |
| Critical care, first 30-74 minutes | 25 | $4,699 | $181 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 27 | $3,003 | $111 |
| Insertion of guide wire with dilation of esophagus using a flexible endoscope | 20 | $2,856 | $136 |
| Insertion of stomach tube using a flexible endoscope | 17 | $2,836 | $167 |
| Removal of stone or debris from bile or pancreatic duct using a flexible endoscope | 13 | $2,413 | $186 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 19 | $1,525 | $80 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $1,523 | $85 |
| New patient visit (15+ min) | 23 | $1,115 | $48 |
| Incision of pancreatic outlet using a flexible endoscope | 14 | $967 | $69 |
| Short return visit | 19 | $651 | $34 |
2014: 17 services
| Biopsy of large bowel using a flexible endoscope | 77 | $11,721 | $150 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 46 | $10,932 | $238 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 117 | $9,743 | $81 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 54 | $8,990 | $163 |
| New patient visit (45+ min) | 64 | $8,012 | $125 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 75 | $7,676 | $58 |
| Return visit (30+ min) | 77 | $6,374 | $75 |
| Diagnostic exam of large bowel using a flexible endoscope | 37 | $6,264 | $169 |
| Short return visit (20+ min) | 86 | $6,255 | $54 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 47 | $5,537 | $111 |
| Pathology examination of tissue using a microscope, intermediate complexity | 73 | $4,581 | $27 |
| New patient visit (30+ min) | 51 | $3,988 | $78 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 20 | $2,180 | $95 |
| Insertion of guide wire with dilation of esophagus using a flexible endoscope | 15 | $2,040 | $136 |
| Critical care, first 30-74 minutes | 11 | $1,970 | $179 |
| New patient visit (15+ min) | 19 | $818 | $43 |
| Short return visit | 19 | $710 | $32 |
2013: 17 services
| Biopsy of large bowel using a flexible endoscope | 71 | $10,409 | $145 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 102 | $10,360 | $96 |
| New patient visit (45+ min) | 86 | $9,850 | $115 |
| Diagnostic exam of large bowel using a flexible endoscope | 51 | $8,285 | $162 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 33 | $7,835 | $237 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 45 | $7,174 | $159 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 62 | $6,762 | $107 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 66 | $6,389 | $57 |
| Return visit (30+ min) | 68 | $6,143 | $81 |
| Short return visit (20+ min) | 75 | $5,308 | $52 |
| New patient visit (30+ min) | 52 | $3,897 | $75 |
| Pathology examination of tissue using a microscope, intermediate complexity | 63 | $3,563 | $28 |
| Insertion of stomach tube using a flexible endoscope | 14 | $3,010 | $201 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 20 | $2,404 | $109 |
| Special stained specimen slides to identify organisms including interpretation and report | 22 | $1,397 | $61 |
| Study of esophagus to assess movement | 11 | $662 | $55 |
| Short return visit | 11 | $399 | $33 |
Medicaid work
$1,304 in 2018
Medicaid paid $1,304 for 146 billed services this clinician did in 2018, up to 30 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 105 | $791 |
| New patient visit (30+ min) | 28 | $344 |
| Short return visit (20+ min) | 13 | $169 |
| 2018 | 146 | 3 | 30 | $1,304 |
Drugs they prescribed that Part D paid
$914,444
Pharmacies billed $914,444 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
1,478 generic and 423 brand-name prescriptions · $914,444 in drug cost · 35 antibiotic prescriptions to 16 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Zenpep | 21 | $88,382 | $4,209 |
| Creon | 23 | $75,352 | $3,276 |
| Rinvoq | 12 | $73,973 | $6,164 |
| Linzess | 77 | $61,243 | $795 |
| Motegrity | 40 | $39,180 | $979 |
See all 27 drugs
| Zenpep | 21 | $88,382 | $4,209 |
| Creon | 23 | $75,352 | $3,276 |
| Rinvoq | 12 | $73,973 | $6,164 |
| Linzess | 77 | $61,243 | $795 |
| Motegrity | 40 | $39,180 | $979 |
| Xifaxan | 11 | $32,372 | $2,943 |
| Mesalamine | 68 | $27,372 | $403 |
| Vemlidy | 13 | $17,341 | $1,334 |
| Sod Sulf-Potass Sulf-Mag Sulf | 255 | $16,737 | $66 |
| Dexlansoprazole Dr | 32 | $10,200 | $319 |
| Sucralfate | 68 | $7,019 | $103 |
| Famotidine | 364 | $6,074 | $17 |
| Mesalamine Er | 32 | $4,687 | $146 |
| Pantoprazole | 362 | $4,183 | $12 |
| Mercaptopurine | 12 | $3,901 | $325 |
| Colestipol | 36 | $3,458 | $96 |
| Lubiprostone | 21 | $2,666 | $127 |
| Lactulose | 27 | $1,144 | $42 |
| Lansoprazole | 20 | $895 | $45 |
| Omeprazole | 67 | $879 | $13 |
| Diphenoxylate-Atropine | 18 | $769 | $43 |
| Misoprostol | 11 | $717 | $65 |
| Esomeprazole Magnesium | 48 | $662 | $14 |
| Sulfasalazine | 15 | $660 | $44 |
| Dicyclomine | 13 | $577 | $44 |
| Gavilyte-G | 18 | $315 | $17 |
| Gavilyte-C | 18 | $290 | $16 |
Year by year
| 2024 | 1,901 | 587 | None | 22% | $914,444 |
| 2023 | 1,787 | 558 | None | 28% | $972,448 |
| 2022 | 1,847 | 599 | None | None | $1,153,684 |
| 2021 | 1,654 | 496 | None | None | $949,006 |
| 2020 | 1,540 | 423 | None | None | $953,988 |
| 2019 | 1,122 | 315 | None | None | $443,143 |
| 2018 | 682 | 207 | None | 43% | $310,807 |
| 2017 | 772 | 183 | 0% (0) | 43% | $382,004 |
| 2016 | 904 | 213 | 0% (0) | 48% | $1,076,293 |
| 2015 | 900 | 236 | None | 57% | $1,280,317 |
| 2014 | 845 | 217 | None | 55% | $455,777 |
| 2013 | 858 | 212 | None | 52% | $200,924 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 31 drugs
| Sucraid | 11 | $147,244 | $13,386 |
| Humira(Cf) | 13 | $98,138 | $7,549 |
| Simponi | 12 | $87,085 | $7,257 |
| Rinvoq | 11 | $75,638 | $6,876 |
| Zenpep | 25 | $68,148 | $2,726 |
| Creon | 17 | $53,068 | $3,122 |
| Linzess | 66 | $48,513 | $735 |
| Mesalamine | 59 | $47,643 | $808 |
| Motegrity | 52 | $36,728 | $706 |
| Viberzi | 11 | $16,023 | $1,457 |
| Sod Sulf-Potass Sulf-Mag Sulf | 187 | $14,679 | $78 |
| Mesalamine Er | 34 | $10,226 | $301 |
| Dexlansoprazole Dr | 23 | $9,423 | $410 |
| Lubiprostone | 35 | $7,611 | $217 |
| Sucralfate | 67 | $5,400 | $81 |
| Pantoprazole | 321 | $4,386 | $14 |
| Mercaptopurine | 12 | $4,265 | $355 |
| Colestipol | 56 | $4,032 | $72 |
| Famotidine | 271 | $3,717 | $14 |
| Budesonide Ec | 11 | $2,822 | $257 |
| Suprep | 18 | $2,121 | $118 |
| Omeprazole | 90 | $1,303 | $14 |
| Gavilyte-C | 66 | $1,207 | $18 |
| Sulfasalazine | 22 | $1,099 | $50 |
| Diphenoxylate-Atropine | 16 | $1,063 | $66 |
| Esomeprazole Magnesium | 41 | $961 | $23 |
| Rabeprazole | 17 | $823 | $48 |
| Dicyclomine | 12 | $797 | $66 |
| Lansoprazole | 17 | $778 | $46 |
| Lactulose | 13 | $498 | $38 |
| Prednisone | 18 | $186 | $10 |
2022: 31 drugs
| Humira(Cf) | 22 | $148,673 | $6,758 |
| Simponi | 14 | $96,515 | $6,894 |
| Zenpep | 39 | $93,462 | $2,396 |
| Xifaxan | 29 | $79,877 | $2,754 |
| Creon | 14 | $44,958 | $3,211 |
| Mesalamine | 62 | $44,274 | $714 |
| Motegrity | 49 | $31,290 | $639 |
| Mesalamine Er | 38 | $19,683 | $518 |
| Linzess | 25 | $17,826 | $713 |
| Viberzi | 11 | $15,389 | $1,399 |
| Suprep | 111 | $12,492 | $113 |
| Lubiprostone | 35 | $10,380 | $297 |
| Dexilant | 12 | $8,612 | $718 |
| Budesonide Ec | 14 | $7,685 | $549 |
| Clenpiq | 45 | $7,314 | $163 |
| Dexlansoprazole Dr | 11 | $5,239 | $476 |
| Colestipol | 57 | $4,029 | $71 |
| Mercaptopurine | 15 | $4,008 | $267 |
| Pantoprazole | 327 | $3,913 | $12 |
| Sucralfate | 52 | $3,262 | $63 |
| Sod Sulf-Potass Sulf-Mag Sulf | 39 | $3,163 | $81 |
| Famotidine | 207 | $2,686 | $13 |
| Gavilyte-C | 128 | $2,041 | $16 |
| Esomeprazole Magnesium | 26 | $1,946 | $75 |
| Omeprazole | 129 | $1,632 | $13 |
| Diphenoxylate-Atropine | 23 | $1,463 | $64 |
| Sulfasalazine | 25 | $1,101 | $44 |
| Rabeprazole | 18 | $747 | $41 |
| Entecavir | 11 | $559 | $51 |
| Dicyclomine | 17 | $473 | $28 |
| Prednisone | 16 | $240 | $15 |
2021: 30 drugs
| Humira(Cf) | 25 | $156,064 | $6,243 |
| Xifaxan | 30 | $80,825 | $2,694 |
| Mesalamine | 71 | $53,984 | $760 |
| Creon | 18 | $41,815 | $2,323 |
| Zenpep | 18 | $25,705 | $1,428 |
| Suprep | 233 | $25,620 | $110 |
| Motegrity | 42 | $24,550 | $585 |
| Mesalamine Er | 45 | $19,904 | $442 |
| Dexilant | 27 | $19,501 | $722 |
| Amitiza | 44 | $19,268 | $438 |
| Linzess | 23 | $15,758 | $685 |
| Pepcid | 12 | $15,367 | $1,281 |
| Viberzi | 11 | $14,651 | $1,332 |
| Budesonide Ec | 18 | $8,715 | $484 |
| Esomeprazole Magnesium | 72 | $7,420 | $103 |
| Lubiprostone | 18 | $6,603 | $367 |
| Budesonide Dr | 11 | $4,994 | $454 |
| Colestipol | 47 | $3,624 | $77 |
| Pantoprazole | 224 | $3,009 | $13 |
| Famotidine | 159 | $2,954 | $19 |
| Sucralfate | 43 | $2,169 | $50 |
| Omeprazole | 145 | $1,817 | $13 |
| Diphenoxylate-Atropine | 26 | $1,513 | $58 |
| Cholestyramine | 17 | $1,086 | $64 |
| Sulfasalazine | 19 | $1,082 | $57 |
| Rabeprazole | 21 | $762 | $36 |
| Dicyclomine | 24 | $624 | $26 |
| Prochlorperazine Maleate | 11 | $264 | $24 |
| Gavilyte-C | 13 | $179 | $14 |
| Prednisone | 12 | $118 | $10 |
2020: 30 drugs
| Sucraid | 17 | $217,807 | $12,812 |
| Humira(Cf) | 12 | $85,058 | $7,088 |
| Xifaxan | 29 | $69,733 | $2,405 |
| Mesalamine | 77 | $59,651 | $775 |
| Creon | 22 | $41,900 | $1,905 |
| Amitiza | 78 | $37,029 | $475 |
| Zenpep | 14 | $26,466 | $1,890 |
| Dexilant | 33 | $19,271 | $584 |
| Mesalamine Er | 41 | $18,754 | $457 |
| Linzess | 27 | $18,690 | $692 |
| Suprep | 152 | $15,788 | $104 |
| Vemlidy | 13 | $15,710 | $1,208 |
| Viberzi | 12 | $15,309 | $1,276 |
| Motegrity | 19 | $11,444 | $602 |
| Sucralfate | 57 | $8,318 | $146 |
| Esomeprazole Magnesium | 53 | $7,090 | $134 |
| Budesonide Ec | 14 | $4,689 | $335 |
| Colestipol | 33 | $3,592 | $109 |
| Pantoprazole | 173 | $2,918 | $17 |
| Mercaptopurine | 14 | $2,837 | $203 |
| Plenvu | 21 | $2,538 | $121 |
| Famotidine | 164 | $2,161 | $13 |
| Omeprazole | 142 | $1,639 | $12 |
| Sulfasalazine | 17 | $1,192 | $70 |
| Diphenoxylate-Atropine | 19 | $1,022 | $54 |
| Rabeprazole | 16 | $760 | $48 |
| Dicyclomine | 34 | $743 | $22 |
| Gavilyte-C | 19 | $266 | $14 |
| Spironolactone | 12 | $108 | $9 |
| Furosemide | 13 | $33 | $3 |
2019: 28 drugs
| Xifaxan | 31 | $76,476 | $2,467 |
| Mesalamine | 52 | $39,475 | $759 |
| Dexilant | 69 | $25,911 | $376 |
| Lialda | 16 | $23,390 | $1,462 |
| Amitiza | 45 | $18,415 | $409 |
| Linzess | 17 | $13,984 | $823 |
| Vemlidy | 12 | $12,847 | $1,071 |
| Nexium | 17 | $12,223 | $719 |
| Apriso | 16 | $9,127 | $570 |
| Suprep | 72 | $7,199 | $100 |
| Colestipol | 22 | $2,841 | $129 |
| Misoprostol | 16 | $2,383 | $149 |
| Esomeprazole Magnesium | 38 | $2,310 | $61 |
| Pantoprazole | 107 | $1,681 | $16 |
| Sucralfate | 47 | $1,548 | $33 |
| Moviprep | 13 | $1,397 | $107 |
| Omeprazole | 87 | $1,015 | $12 |
| Ranitidine | 53 | $841 | $16 |
| Famotidine | 65 | $640 | $10 |
| Sulfasalazine | 15 | $625 | $42 |
| Propranolol | 14 | $393 | $28 |
| Proctozone-Hc | 15 | $379 | $25 |
| Constulose | 11 | $373 | $34 |
| Gavilyte-G | 21 | $269 | $13 |
| Dicyclomine | 17 | $196 | $12 |
| Prednisone | 13 | $144 | $11 |
| Spironolactone | 13 | $127 | $10 |
| Furosemide | 12 | $37 | $3 |
2018: 19 drugs
| Humira | 12 | $63,142 | $5,262 |
| Xifaxan | 26 | $53,918 | $2,074 |
| Mesalamine | 24 | $23,620 | $984 |
| Dexilant | 51 | $15,501 | $304 |
| Linzess | 14 | $8,613 | $615 |
| Esomeprazole Magnesium | 34 | $8,178 | $241 |
| Amitiza | 17 | $8,132 | $478 |
| Suprep | 23 | $2,142 | $93 |
| Colestipol | 24 | $2,013 | $84 |
| Clenpiq | 14 | $1,988 | $142 |
| Pantoprazole | 64 | $551 | $9 |
| Constulose | 16 | $540 | $34 |
| Ranitidine | 42 | $456 | $11 |
| Omeprazole | 48 | $448 | $9 |
| Sucralfate | 14 | $389 | $28 |
| Propranolol | 13 | $219 | $17 |
| Peg 3350-Electrolyte | 14 | $116 | $8 |
| Metoclopramide | 15 | $112 | $7 |
| Famotidine | 17 | $65 | $4 |
2017: 21 drugs
| Xifaxan | 14 | $28,012 | $2,001 |
| Dexilant | 82 | $26,223 | $320 |
| Lialda | 19 | $21,862 | $1,151 |
| Amitiza | 38 | $12,733 | $335 |
| Apriso | 17 | $11,030 | $649 |
| Esomeprazole Magnesium | 37 | $8,885 | $240 |
| Linzess | 11 | $5,668 | $515 |
| Prepopik | 22 | $2,762 | $126 |
| Colestipol | 11 | $1,259 | $114 |
| Suprep | 14 | $1,227 | $88 |
| Pantoprazole | 121 | $906 | $7 |
| Lactulose | 25 | $835 | $33 |
| Sucralfate | 25 | $572 | $23 |
| Omeprazole | 39 | $271 | $7 |
| Propranolol | 17 | $253 | $15 |
| Ranitidine | 36 | $240 | $7 |
| Spironolactone | 12 | $182 | $15 |
| Peg 3350-Electrolyte | 12 | $110 | $9 |
| Dicyclomine | 13 | $96 | $7 |
| Famotidine | 16 | $54 | $3 |
| Furosemide | 13 | $27 | $2 |
2016: 23 drugs
| Sovaldi | 12 | $340,146 | $28,346 |
| Xifaxan | 28 | $47,403 | $1,693 |
| Lialda | 31 | $32,917 | $1,062 |
| Dexilant | 96 | $27,617 | $288 |
| Apriso | 27 | $11,453 | $424 |
| Amitiza | 21 | $9,204 | $438 |
| Linzess | 12 | $8,126 | $677 |
| Nexium | 11 | $7,990 | $726 |
| Carafate | 16 | $6,573 | $411 |
| Prepopik | 43 | $4,907 | $114 |
| Esomeprazole Magnesium | 21 | $3,558 | $169 |
| Colestipol | 17 | $2,787 | $164 |
| Sucralfate | 38 | $898 | $24 |
| Pantoprazole | 106 | $817 | $8 |
| Omeprazole | 80 | $773 | $10 |
| Constulose | 12 | $577 | $48 |
| Lactulose | 23 | $573 | $25 |
| Propranolol | 12 | $350 | $29 |
| Ranitidine | 16 | $267 | $17 |
| Gavilyte-C | 18 | $199 | $11 |
| Gavilyte-G | 13 | $165 | $13 |
| Peg 3350-Electrolyte | 17 | $164 | $10 |
| Dicyclomine | 19 | $106 | $6 |
2015: 26 drugs
| Harvoni | 16 | $511,220 | $31,951 |
| Sovaldi | 15 | $418,628 | $27,909 |
| Simponi | 11 | $51,247 | $4,659 |
| Humira | 14 | $45,759 | $3,269 |
| Lialda | 36 | $39,894 | $1,108 |
| Uceris | 17 | $24,193 | $1,423 |
| Xifaxan | 14 | $23,679 | $1,691 |
| Dexilant | 75 | $21,038 | $281 |
| Apriso | 35 | $14,228 | $407 |
| Nexium | 20 | $12,348 | $617 |
| Amitiza | 31 | $10,618 | $343 |
| Linzess | 13 | $7,351 | $565 |
| Moviprep | 67 | $5,414 | $81 |
| Mercaptopurine | 15 | $2,757 | $184 |
| Colestipol | 29 | $2,488 | $86 |
| Prepopik | 14 | $1,513 | $108 |
| Omeprazole | 97 | $938 | $10 |
| Pantoprazole | 77 | $658 | $9 |
| Dicyclomine | 12 | $620 | $52 |
| Sucralfate | 16 | $492 | $31 |
| Lactulose | 23 | $481 | $21 |
| Propranolol | 18 | $384 | $21 |
| Metronidazole | 11 | $364 | $33 |
| Spironolactone | 15 | $294 | $20 |
| Peg 3350-Electrolyte | 16 | $156 | $10 |
| Gavilyte-C | 12 | $142 | $12 |
2014: 20 drugs
| Humira | 33 | $93,347 | $2,829 |
| Lialda | 37 | $42,967 | $1,161 |
| Dexilant | 117 | $26,428 | $226 |
| Apriso | 23 | $8,024 | $349 |
| Amitiza | 28 | $7,921 | $283 |
| Carafate | 18 | $5,674 | $315 |
| Protonix | 19 | $5,628 | $296 |
| Moviprep | 58 | $4,642 | $80 |
| Prepopik | 22 | $1,822 | $83 |
| Omeprazole | 115 | $1,413 | $12 |
| Dicyclomine | 14 | $1,104 | $79 |
| Mercaptopurine | 12 | $916 | $76 |
| Colestipol | 11 | $875 | $80 |
| Sucralfate | 32 | $875 | $27 |
| Pantoprazole | 54 | $529 | $10 |
| Lactulose | 16 | $488 | $30 |
| Spironolactone | 14 | $384 | $27 |
| Peg 3350-Electrolyte | 17 | $186 | $11 |
| Gavilyte-C | 11 | $118 | $11 |
| Propranolol | 14 | $112 | $8 |
2013: 24 drugs
| Humira | 14 | $37,665 | $2,690 |
| Lialda | 27 | $32,630 | $1,209 |
| Dexilant | 111 | $19,239 | $173 |
| Amitiza | 30 | $9,301 | $310 |
| Aciphex | 28 | $9,195 | $328 |
| Nexium | 14 | $6,391 | $456 |
| Carafate | 20 | $5,272 | $264 |
| Apriso | 12 | $3,842 | $320 |
| Moviprep | 50 | $3,598 | $72 |
| Omeprazole | 103 | $1,792 | $17 |
| Colestipol | 34 | $1,179 | $35 |
| Lansoprazole | 11 | $1,007 | $92 |
| Suprep | 12 | $796 | $66 |
| Sucralfate | 25 | $793 | $32 |
| Pantoprazole | 53 | $734 | $14 |
| Ondansetron | 11 | $621 | $56 |
| Lactulose | 18 | $596 | $33 |
| Metoclopramide | 26 | $295 | $11 |
| Generlac | 13 | $282 | $22 |
| Peg 3350-Electrolyte | 16 | $169 | $11 |
| Propranolol | 19 | $125 | $7 |
| Prednisone | 18 | $104 | $6 |
| Ranitidine | 15 | $71 | $5 |
| Famotidine | 11 | $64 | $6 |
Money from drug and device companies
$3,067 in 2025
| 2025 | 16 | 136 | None | $3,067 |
| 2024 | 20 | 95 | None | $2,203 |
| 2023 | 19 | 80 | None | $1,947 |
| 2022 | 18 | 112 | None | $2,115 |
| 2021 | 11 | 70 | None | $984 |
| 2020 | 14 | 70 | None | $1,159 |
| 2019 | 15 | 114 | None | $1,712 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Rinvoq | $1,185 | 60 payments
|
| Madrigal Pharmaceuticals | Rezdiffra | $391 | 8 payments
|
| Janssen Biotech | Tremfya | $317 | 23 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $292 | 12 payments
|
| Aimmune Therapeutics | Vowst | $204 | 8 payments
|
| Phathom Pharmaceuticals | Voquezna | $186 | 5 payments
|
See all 136 published payments
| Abbvie | Meals · 2025-12-22 | Skyrizi | $13 |
| Phathom Pharmaceuticals | Meals · 2025-12-17 | Voquezna | $125 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-12-09 | Entyvio | $29 |
| Abbvie | Meals · 2025-12-08 | Rinvoq | $10 |
| Pfizer | Meals · 2025-12-08 | Velsipity | $14 |
| Janssen Biotech | Meals · 2025-12-05 | Tremfya | $20 |
| Novo Nordisk | Meals · 2025-12-04 | Wegovy | $27 |
| Novo Nordisk | Meals · 2025-12-02 | Wegovy | $19 |
| Abbvie | Meals · 2025-12-02 | Mavyret | $25 |
| Abbvie | Meals · 2025-12-01 | Rinvoq | $24 |
| Janssen Biotech | Meals · 2025-11-25 | Tremfya | $24 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-11-24 | Xifaxan | $24 |
| Phathom Pharmaceuticals | Meals · 2025-11-21 | Voquezna | $15 |
| Phathom Pharmaceuticals | Meals · 2025-11-21 | Voquezna | $2 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-11-20 | Entyvio | $27 |
| Abbvie | Meals · 2025-11-18 | Viberzi | $10 |
| Abbvie | Meals · 2025-11-17 | Skyrizi | $12 |
| Aimmune Therapeutics | Meals · 2025-11-12 | Zenpep | $10 |
| Aimmune Therapeutics | Meals · 2025-11-11 | Zenpep | $11 |
| Pfizer | Meals · 2025-11-03 | Velsipity | $17 |
| Abbvie | Meals · 2025-10-30 | Skyrizi | $25 |
| Madrigal Pharmaceuticals | Meals · 2025-10-22 | Rezdiffra | $146 |
| Janssen Biotech | Meals · 2025-10-21 | Tremfya | $26 |
| Janssen Biotech | Meals · 2025-10-20 | Tremfya | $10 |
| Abbvie | Meals · 2025-10-17 | Rinvoq | $25 |
| Madrigal Pharmaceuticals | Meals · 2025-10-17 | Rezdiffra | $21 |
| Abbvie | Meals · 2025-10-13 | Linzess | $22 |
| Pfizer | Meals · 2025-10-13 | Velsipity | $18 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-10-09 | Entyvio | $32 |
| Abbvie | Meals · 2025-10-06 | Rinvoq | $11 |
| Madrigal Pharmaceuticals | Meals · 2025-10-06 | Rezdiffra | $50 |
| Abbvie | Meals · 2025-10-01 | Skyrizi | $23 |
| Genzyme | Meals · 2025-09-30 | Dupixent | $30 |
| Abbvie | Meals · 2025-09-29 | Rinvoq | $10 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-09-29 | Xifaxan | $33 |
| Abbvie | Meals · 2025-09-26 | Rinvoq | $21 |
| Abbvie | Meals · 2025-09-25 | Viberzi | $10 |
| Abbvie | Meals · 2025-09-25 | Mavyret | $19 |
| Janssen Pharmaceuticals | Meals · 2025-09-22 | Tremfya | $11 |
| Madrigal Pharmaceuticals | Meals · 2025-09-19 | Rezdiffra | $41 |
| Aimmune Therapeutics | Meals · 2025-09-16 | Vowst | $23 |
| Abbvie | Meals · 2025-09-12 | Rinvoq | $22 |
| Abbvie | Meals · 2025-09-10 | Rinvoq | $13 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-09-09 | Entyvio | $26 |
| Janssen Biotech | Meals · 2025-09-08 | Tremfya | $1 |
| Janssen Biotech | Meals · 2025-09-08 | Tremfya | $11 |
| Abbvie | Meals · 2025-09-06 | Creon | $19 |
| Abbvie | Meals · 2025-09-03 | Rinvoq | $24 |
| Abbvie | Meals · 2025-08-18 | Rinvoq | $24 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-08-12 | Entyvio | $26 |
| Aimmune Therapeutics | Meals · 2025-08-12 | Vowst | $34 |
| Abbvie | Meals · 2025-08-06 | Rinvoq | $21 |
| Abbvie | Meals · 2025-08-05 | Rinvoq | $18 |
| Janssen Biotech | Meals · 2025-07-30 | Tremfya | $7 |
| Abbvie | Meals · 2025-07-29 | Rinvoq | $19 |
| Janssen Biotech | Meals · 2025-07-21 | Tremfya | $1 |
| Janssen Biotech | Meals · 2025-07-21 | Tremfya | $12 |
| Abbvie | Meals · 2025-07-11 | Skyrizi | $30 |
| Abbvie | Meals · 2025-07-09 | Rinvoq | $24 |
| Abbvie | Meals · 2025-07-07 | Rinvoq | $10 |
| Gilead Sciences | Meals · 2025-07-07 | None | $29 |
| Genzyme | Meals · 2025-07-01 | Dupixent | $45 |
| QOL Medical | Meals · 2025-06-30 | Sucraid | $31 |
| Abbvie | Meals · 2025-06-30 | Rinvoq | $11 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-06-27 | Entyvio | $20 |
| Abbvie | Meals · 2025-06-20 | Rinvoq | $27 |
| Abbvie | Meals · 2025-06-13 | Rinvoq | $23 |
| Aimmune Therapeutics | Meals · 2025-06-11 | Vowst | $31 |
| Madrigal Pharmaceuticals | Meals · 2025-06-10 | Rezdiffra | $30 |
| Abbvie | Meals · 2025-06-09 | Rinvoq | $10 |
| Abbvie | Meals · 2025-06-06 | Creon | $25 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-06-06 | Entyvio | $13 |
| Abbvie | Meals · 2025-06-05 | Mavyret | $24 |
| Abbvie | Meals · 2025-06-02 | Rinvoq | $21 |
| Abbvie | Meals · 2025-06-02 | Skyrizi | $24 |
| Abbvie | Meals · 2025-05-27 | Rinvoq | $28 |
| Janssen Biotech | Meals · 2025-05-23 | Tremfya | $20 |
| Lilly USA | Meals · 2025-05-23 | Omvoh | $33 |
| Janssen Biotech | Meals · 2025-05-19 | Tremfya | $13 |
| Abbvie | Meals · 2025-05-16 | Skyrizi | $28 |
| Abbvie | Meals · 2025-05-15 | Mavyret | $25 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-05-14 | Entyvio | $43 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-05-09 | Entyvio | $11 |
| Abbvie | Meals · 2025-05-05 | Rinvoq | $12 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-05-05 | Relistor | $24 |
| Aimmune Therapeutics | Meals · 2025-05-04 | Vowst | $33 |
| Madrigal Pharmaceuticals | Meals · 2025-05-02 | Rezdiffra | $31 |
| Abbvie | Meals · 2025-04-29 | Skyrizi | $22 |
| Celltrion USA | Meals · 2025-04-29 | Vegzelma | $24 |
| Abbvie | Meals · 2025-04-23 | Rinvoq | $27 |
| Janssen Biotech | Meals · 2025-04-11 | Tremfya | $20 |
| Abbvie | Meals · 2025-04-11 | Creon | $5 |
| Abbvie | Meals · 2025-04-10 | Mavyret | $25 |
| Abbvie | Meals · 2025-04-09 | Skyrizi | $25 |
| Abbvie | Meals · 2025-04-08 | Linzess | $23 |
| Phathom Pharmaceuticals | Meals · 2025-04-08 | Voquezna | $22 |
| Janssen Biotech | Meals · 2025-04-07 | Tremfya | $10 |
| Janssen Biotech | Meals · 2025-04-07 | Tremfya | $1 |
| Janssen Biotech | Meals · 2025-04-04 | Tremfya | $28 |
| Abbvie | Meals · 2025-04-04 | Mavyret | $10 |
| Abbvie | Meals · 2025-04-03 | Rinvoq | $20 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-03-31 | Entyvio | $27 |
| Janssen Biotech | Meals · 2025-03-28 | Tremfya | $22 |
| Abbvie | Meals · 2025-03-27 | Linzess | $12 |
| Abbvie | Meals · 2025-03-27 | Rinvoq | $29 |
| Janssen Biotech | Meals · 2025-03-24 | Tremfya | $0 |
| Janssen Biotech | Meals · 2025-03-24 | Tremfya | $37 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-03-17 | Xifaxan | $24 |
| Janssen Biotech | Meals · 2025-03-14 | Tremfya | $15 |
| Abbvie | Meals · 2025-03-14 | Rinvoq | $26 |
| CapsoVision | Meals · 2025-03-12 | Capsocam Plus | $15 |
| Madrigal Pharmaceuticals | Meals · 2025-03-11 | Rezdiffra | $39 |
| Abbvie | Meals · 2025-03-10 | Skyrizi | $14 |
| Abbvie | Meals · 2025-03-06 | Skyrizi | $31 |
| Janssen Biotech | Meals · 2025-03-05 | Tremfya | $6 |
| Abbvie | Meals · 2025-03-03 | Viberzi | $26 |
| Janssen Biotech | Meals · 2025-02-24 | Tremfya | $1 |
| Janssen Biotech | Meals · 2025-02-24 | Tremfya | $10 |
| Genzyme | Meals · 2025-02-21 | Dupixent | $32 |
| Abbvie | Meals · 2025-02-18 | Linzess | $20 |
| Abbvie | Meals · 2025-02-14 | Rinvoq | $25 |
| Madrigal Pharmaceuticals | Meals · 2025-02-11 | Rezdiffra | $33 |
| Aimmune Therapeutics | Meals · 2025-02-10 | Vowst | $28 |
| Janssen Biotech | Meals · 2025-02-06 | Tremfya | $21 |
| Abbvie | Meals · 2025-02-06 | Rinvoq | $20 |
| Abbvie | Meals · 2025-02-03 | Skyrizi | $11 |
| Pfizer | Meals · 2025-02-03 | Xeljanz | $16 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-01-30 | Entyvio | $20 |
| Abbvie | Meals · 2025-01-29 | Mavyret | $23 |
| Abbvie | Meals · 2025-01-28 | Skyrizi | $20 |
| Abbvie | Meals · 2025-01-27 | Rinvoq | $22 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-01-23 | Xifaxan | $25 |
| Aimmune Therapeutics | Meals · 2025-01-13 | Vowst | $34 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-01-07 | Entyvio | $18 |
| Abbvie | Meals · 2025-01-06 | Skyrizi | $10 |
| Phathom Pharmaceuticals | Meals · 2025-01-04 | Voquezna | $22 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $2,203
| Abbvie | Rinvoq | $831 | 37 payments
|
| Janssen Biotech | Stelara | $255 | 18 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $232 | 9 payments
|
| Genzyme | Dupixent | $206 | 7 payments
|
| Madrigal Pharmaceuticals | Rezdiffra | $175 | 4 payments
|
| Lilly USA | Omvoh | $82 | 3 payments
|
| QOL Medical | Sucraid | $55 | 2 payments
|
| Echosens North America | Fibroscan | $47 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $46 | 2 payments
|
| Aimmune Therapeutics | Zenpep | $41 | 1 payment
|
| Fresenius Kabi USA | Idacio | $39 | 1 payment
|
| Pfizer | Xeljanz | $37 | 2 payments
|
| Intercept Pharmaceuticals | Ocaliva | $27 | 1 payment
|
| Phathom Pharmaceuticals | Voquezna | $27 | 1 payment
|
| Laborie Medical Technologies | None | $23 | 1 payment
|
| Mallinckrodt Hospital Products | Terlivaz | $21 | 1 payment
|
| Ardelyx | Ibsrela | $17 | 1 payment
|
| Olympus America | Evis Exera III Colonovideoscope | $15 | 1 payment
|
| Ferring Pharmaceuticals | Rebyota | $15 | 1 payment
|
| Endogastric Solutions | Esophyx | $12 | 1 payment
|
2023: $1,947
| AbbVie | Rinvoq | $724 | 30 payments
|
| Celgene | Zeposia | $204 | 11 payments
|
| Genzyme | Dupixent | $150 | 6 payments
|
| Janssen Biotech | Stelara | $142 | 5 payments
|
| Endogastric Solutions | Esophyx | $134 | 2 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Trulance | $82 | 4 payments
|
| Nestle Healthcare Nutrition | Zenpep | $67 | 2 payments
|
| Merck Sharp & Dohme | Dificid | $66 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $65 | 3 payments
|
| Intercept Pharmaceuticals | Ocaliva | $55 | 3 payments
|
| QOL Medical | Sucraid | $53 | 2 payments
|
| Sandoz | Hyrimoz | $50 | 2 payments
|
| Pfizer | Xeljanz | $33 | 2 payments
|
| Boston Scientific | Radial Jaw 4 | $31 | 1 payment
|
| Fresenius Kabi USA | Idacio | $29 | 1 payment
|
| Regeneron Healthcare Solutions | Dupixent | $19 | 1 payment
|
| Daiichi Sankyo | Injectafer | $18 | 1 payment
|
| Braintree Laboratories | Sutab | $14 | 1 payment
|
| Exact Sciences | Cologuard Collection Kit | $13 | 1 payment
|
2022: $2,115
| Abbvie | Skyrizi | $829 | 48 payments
|
| Celgene | Zeposia | $251 | 15 payments
|
| Nestle HealthCare Nutrition | Zenpep | $214 | 9 payments
|
| Takeda Pharmaceuticals U.S.A. | Gattex | $149 | 7 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Trulance | $146 | 9 payments
|
| Genzyme | Dupixent | $91 | 4 payments
|
| Pfizer | Xeljanz | $91 | 6 payments
|
| Endogastric Solutions | Esophyx | $86 | 1 payment
|
| Merck Sharp & Dohme | Dificid | $38 | 2 payments
|
| Janssen Biotech | Stelara | $37 | 2 payments
|
| RedHill Biopharma | Talicia | $34 | 2 payments
|
| Organon | None | $27 | 1 payment
|
| Intercept Pharmaceuticals | Ocaliva | $26 | 1 payment
|
| Regeneron Healthcare Solutions | Dupixent | $25 | 1 payment
|
| Ardelyx | Ibsrela | $23 | 1 payment
|
| Daiichi Sankyo | Injectafer | $23 | 1 payment
|
| Gilead Sciences | None | $15 | 1 payment
|
| Ironwood Pharmaceuticals | Linzess | $12 | 1 payment
|
2021: $984
| AbbVie | Humira | $410 | 33 payments
|
| Nestle HealthCare Nutrition | Zenpep | $170 | 11 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $76 | 5 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $69 | 4 payments
|
| Celgene | Zeposia | $68 | 4 payments
|
| Merck Sharp & Dohme | Dificid | $65 | 4 payments
|
| Gilead Sciences | None | $43 | 3 payments
|
| Pfizer | Xeljanz | $30 | 2 payments
|
| Janssen Biotech | Stelara | $28 | 2 payments
|
| Intercept Pharmaceuticals | Ocaliva | $14 | 1 payment
|
| Ironwood Pharmaceuticals | Linzess | $12 | 1 payment
|
2020: $1,159
| AbbVie | Humira | $418 | 23 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $139 | 10 payments
|
| Janssen Biotech | Stelara | $95 | 7 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $88 | 6 payments
|
| Merck Sharp & Dohme | Dificid | $82 | 5 payments
|
| Romark Laboratories LC | Alinia | $64 | 3 payments
|
| Gilead Sciences | None | $61 | 3 payments
|
| QOL Medical | Sucraid | $59 | 4 payments
|
| RedHill Biopharma | Talicia | $39 | 2 payments
|
| Intercept Pharmaceuticals | Ocaliva | $32 | 2 payments
|
| Alfasigma USA | None | $30 | 2 payments
|
| Braintree Laboratories | Suprep Bowel Prep | $20 | 1 payment
|
| Daiichi Sankyo | Injectafer | $16 | 1 payment
|
| Pfizer | Xeljanz | $16 | 1 payment
|
2019: $1,712
| AbbVie | Humira | $360 | 14 payments
|
| Takeda Pharmaceuticals U.S.A. | Amitiza | $228 | 17 payments
|
| QOL Medical | Sucraid | $193 | 26 payments
|
| Janssen Biotech | Stelara | $188 | 12 payments
|
| Gilead Sciences | Vemlidy | $173 | 8 payments
|
| Pfizer | Xeljanz | $151 | 10 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $132 | 9 payments
|
| Merck Sharp & Dohme | Dificid | $92 | 6 payments
|
| Romark Laboratories LC | Alinia | $66 | 5 payments
|
| Braintree Laboratories | Suprep Bowel Prep | $37 | 2 payments
|
| Shionogi | Mulpleta | $21 | 1 payment
|
| Allergan | Viberzi | $19 | 1 payment
|
| Ironwood Pharmaceuticals | Linzess | $18 | 1 payment
|
| AMAG Pharmaceuticals | Feraheme | $17 | 1 payment
|
| Boston Scientific | Captivator Cold | $16 | 1 payment
|
Professional record
- NPI
- 1598804346
- Licence
- CA A54545, MT 117660California A54545: Current · expires 2027-03-31
- Trained
- Howard University College of Medicine, 1994 · 32 years ago
- Group
- Capitol Gastroenterology Consultants Medical Group Inc · Benefis Hospitals Inc
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RG0100X (207RG0100X)
- Mailing address
- 1860 Sierra Gardens Dr Unit 850, Roseville, CA, 95661
- NPI first listed
- 2007-02-06
- NPI last updated
- 2026-03-30
- NPI record certified
- 2026-03-30
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1101 26th St S, Great Falls, MT, 59405